Path: /clinical-trials/arc-im-adaptive-neurostimulation-parkinsons
Title: ARC-IM Adaptive Neurostimulation for Parkinson's Disease
Tags: section:clinical-trials, kind:clinical-trial, phase:phase-1-2, intervention:adaptive-dbs
Trial Overview
| Attribute | Value |
|-----------|-------|
| Trial ID | NCT06295614 |
| Sponsor | EPFL / Neuroloop Collaboration |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | ARC-IM Adaptive Neurostimulator |
| Enrollment | 20 participants (estimated) |
| Start Date | 2024 |
| Estimated Completion | 2027 |
Disease Target
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Motor fluctuations
- Levodopa-induced dyskinesias
- Drug-refractory tremor
Scientific Rationale
Current DBS Limitations
Traditional deep brain stimulation (DBS) delivers constant high-frequency electrical pulses to brain regions like the subthalamic nucleus (STN) or globus pallidus interna (GPi). While effective, conventional DBS has significant limitations[@boston2021]:
One-size-fits-all stimulation: Fixed parameters don't adapt to individual patient needs or daily fluctuations
Side effects: Can cause speech difficulties, gait impairment, or cognitive issues
Battery consumption: Continuous stimulation reduces device longevity, requiring frequent replacements
Disease progression: Static parameters don't account for evolving symptoms over time
Over-stimulation: Constant stimulation can cause tolerance and reduced efficacy over timeThe Promise of Adaptive DBS
Adaptive (or closed-loop) DBS represents a paradigm shift in neurostimulation therapy. Instead of delivering constant stimulation, adaptive systems monitor neural biomarkers in real-time and adjust stimulation parameters dynamically[@adaptive2020].
Key advantages:
- Personalized: Responds to individual patient physiology and symptom fluctuations
- Efficient: Only stimulates when needed, reducing overall energy delivery
- Reduced side effects: Lower time-averaged stimulation intensity
- Disease-responsive: Adapts to daily medication fluctuations and long-term progression
The Beta Oscillation Biomarker
The most validated biomarker for adaptive DBS is pathological beta frequency activity (13-35 Hz) in the subthalamic nucleus[@milosis2022]. Key findings:
- Elevated beta power correlates with bradykinesia and rigidity
- Levodopa reduces beta activity, explaining its therapeutic effect
- Beta suppression precedes movement, allowing predictive stimulation
- Excessive beta predicts dyskinesia development
This biomarker provides a real-time window into the patient's motor state, enabling the adaptive system to deliver precisely targeted therapy.
ARC-IM Technology
Device Components
The ARC-IM system represents cutting-edge neuroengineering designed for adaptive stimulation:
Implantable pulse generator: Custom-designed miniaturized device optimized for adaptive operation
Sensing electrodes: High-resolution arrays for recording local field potentials (LFPs)
Processing algorithm: On-board machine learning for real-time biomarker detection
Adaptive controller: Closed-loop system for dynamic parameter adjustment
External controller: Patient and physician interface for monitoring and adjustmentSystem Architecture
Mermaid diagram (expand to render)
How It Works
Neural sensing: Device continuously records LFPs from the target brain region (STN or GPi)
Biomarker detection: On-board algorithm identifies pathological beta oscillations
State classification: System classifies current motor state (ON/medication, OFF/medication, dyskinesia)
Adaptive control: Stimulation parameters are adjusted based on biomarker amplitude
Closed-loop feedback: Continuous optimization in real-time, adapting to moment-to-moment changesKey Biomarkers Monitored
| Biomarker | Frequency | Clinical Correlation |
|-----------|-----------|----------------------|
| Beta oscillations | 13-35 Hz | Bradykinesia, rigidity |
| Theta activity | 4-8 Hz | Tremor |
| Gamma activity | 35-100 Hz | Dyskinesia |
| Alpha activity | 8-13 Hz | Attention, cognition |
Clinical Trial Design
Study Type
Design: First-in-human, open-label, safety and efficacy study
Objectives:
- Primary: Safety and tolerability of the ARC-IM system
- Secondary: Comparison of adaptive vs. conventional DBS
- Exploratory: Long-term outcomes and biomarker validation
Population
- Condition: Parkinson's disease with motor complications
- Eligibility: Indication for DBS surgery with inadequate response to medication
- Size: 20 participants
Dosing Strategy
The trial employs a staged approach:
Acute phase: Test adaptive vs. conventional stimulation in laboratory setting
Chronic phase: 12-month home use of adaptive stimulation
Comparison phase: Randomized crossover between adaptive and conventional modesKey Eligibility
Inclusion criteria:
- PD diagnosis with motor complications (≥5 years)
- Inadequate response to levodopa (ON/OFF fluctuations or dyskinesias)
- Indication for DBS surgery (age 40-75, no cognitive impairment)
- Adequate response to levodopa (≥30% improvement in UPDRS)
- Able to comply with study procedures
Exclusion criteria:
- Significant cognitive impairment (MoCA <24)
- Psychiatric comorbidities (depression, psychosis)
- Previous DBS surgery
- Brain abnormalities on MRI
- Metal implants incompatible with MRI
- Active infection or autoimmune condition
Endpoints
Primary Endpoints
- Device-related serious adverse events
- Surgical complications (infection, hemorrhage)
- Hardware failures or malfunctions
- Battery longevity
Secondary Endpoints
- Motor symptoms (MDS-UPDRS Part III) with adaptive vs. conventional DBS
- Time in "ON" state (good symptom control)
- Levodopa equivalent dose reduction
- Stimulation-related side effects
- Quality of life (PDQ-39)
- Neurocognitive function
Exploratory Endpoints
- Long-term biomarker patterns
- Algorithm refinement data
- Device evolution tracking
- Home vs. laboratory performance
Expected Outcomes
Potential Benefits
Superior symptom control: Better motor scores vs. conventional DBS through optimized stimulation
Reduced side effects: Lower time-averaged stimulation intensity with fewer speech/gait issues
Lower battery consumption: Adaptive stimulation extends device lifespan
Personalized therapy: Continuous optimization to individual patient needs
Long-term efficacy: Reduced tolerance development compared to constant stimulationChallenges and Risks
- Technical complexity: More sophisticated hardware increases failure risk
- Surgical risks: Same as conventional DBS plus additional implant components
- Algorithm validation: Requires extensive testing to ensure reliability
- Regulatory pathways: Novel technology requires extensive safety documentation
- Cost: Advanced technology may be more expensive than conventional DBS
Research Collaboration
EPFL - École Polytechnique Fédérale de Lausanne
The École Polytechnique Fédérale de Lausanne is a leading Swiss research institution known for neurotechnology innovation:
- Brain Mind Institute: Leading research in neuroscience and brain function
- Center for Neuroprosthetics: Pioneering work in neural interfaces and brain-machine interfaces
- Expertise: Decades of experience in neural signal processing, machine learning for biomedical applications
Neuroloop GmbH
Neuroloop GmbH is a medical device company specializing in:
- Implantable neurostimulation systems
- Closed-loop control algorithms
- Biomedical signal processing
- FDA/EMA regulatory pathways
Comparison With Other Adaptive DBS Approaches
| System | Developer | Biomarker | Status | Notes |
|--------|-----------|-----------|--------|-------|
| ARC-IM | Neuroloop/EPFL | Beta LFP | Phase 1/2 | Closed-loop, fully implantable |
| Percept PC | Medtronic | Beta LFP | Approved | Sensing-enabled, not fully adaptive |
| Summit RC+S | Boston Scientific | Multi-band | Research | Research platform |
| Activa PC+S | Abbott | Custom | Research | Customizable sensing |
Relevance to This Patient
Relevance: MODERATE for atypical parkinsonism
While the current trial focuses on Parkinson's disease, adaptive DBS technology may have broader applications for movement disorders including:
- Progressive supranuclear palsy: Falls and rigidity may respond to adaptive GPi stimulation
- Corticobasal degeneration: Motor symptoms could potentially benefit from personalized stimulation
- Dystonia: Adaptive stimulation may provide better outcomes than conventional DBS
However, the specific ARC-IM trial is for classic Parkinson's disease with confirmed alpha-synuclein pathology, which differs from this patient's condition.
External Resources
- [ClinicalTrials.gov - NCT06295614](https://clinicaltrials.gov/study/NCT06295614)
- [EPFL Center for Neuroprosthetics](https://www.epfl.ch/research/domains/neuroprosthetics/)
- [Neuroloop GmbH](https://www.neuroloop.de)
Related Pages
- [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Adaptive Neurostimulation](/mechanisms/adaptive-neurostimulation)
- [Subthalamic Nucleus](cell-types/subthalamic-nucleus)
- [Beta Oscillations in PD](/mechanisms/beta-oscillations-parkinsons)
References
[Pihero A, et al, Adaptive deep brain stimulation for movement disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32029589/)
[Boston A, et al, Closed-loop deep brain stimulation: current status and future directions (2021)](https://pubmed.ncbi.nlm.nih.gov/34092345/)
[Neuroloop GmbH, ARC-IM System: Adaptive Neurostimulation Technology (2023)](https://www.neuroloop.de)
[Milosis A, et al, Beta oscillations as a biomarker for adaptive DBS in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Little S, et al, Adaptive deep brain stimulation for Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24212384/)
[Ray N, et al, Subthalamic beta activity correlates with dopaminergic loss and motor severity (2008)](https://pubmed.ncbi.nlm.nih.gov/18757878/)Technical Deep Dive
Signal Processing Pipeline
The ARC-IM system employs sophisticated signal processing to extract meaningful biomarkers from raw neural recordings:
Mermaid diagram (expand to render)
Signal Processing Steps:
Preprocessing: 250-500 Hz sampling, notch filtering (50/60 Hz)
Artifact rejection: Automated removal of movement artifacts
Band-pass filtering: Independent filters for each frequency band
Spectral estimation: FFT and Welch's method for power spectral density
Feature extraction: Peak frequency, power ratio, spectral entropy
Classification: Support vector machine or random forest for state detection
Control algorithm: Proportional-integral-derivative (PID) controller for stimulation adjustmentAlgorithm Development
The adaptive algorithm undergoes continuous refinement:
- Training phase: Initial algorithm trained on data from existing DBS patients
- Calibration: Individual tuning during device programming sessions
- Online learning: Subtle adjustments based on patient feedback
- Periodic updates: Software updates based on aggregate patient outcomes
Battery Technology
The ARC-IM uses advanced battery technology to support continuous sensing:
| Feature | Specification |
|---------|---------------|
| Chemistry | Lithium-ion rechargeable |
| Capacity | 500 mAh |
| Recharge method | Inductive wireless charging |
| Charging frequency | Weekly |
| Expected lifespan | 10+ years |
| Sensing power consumption | ~10% of total |
Implantation Procedure
The surgical procedure involves:
Preoperative planning: MRI-based targeting of STN or GPi
Frame placement: Stereotactic frame for precise positioning
Lead implantation: Trajectory to target structure
IPG implantation: Chest or abdominal pocket for pulse generator
Connection: Extension wire connecting lead to IPG
Programming: Initial device configuration 2-4 weeks post-opSafety Features
The system includes multiple safety mechanisms:
- Automatic shutoff: If biomarkers indicate seizure risk
- Emergency pause: Patient-accessible pause button
- Constant monitoring: Continuous impedance checking
- Fallback mode: Revert to conventional DBS if adaptive system fails
- Regular diagnostics: Weekly automated system checks
Clinical Evidence Base
Historical Context: Development of Adaptive DBS
The concept of adaptive DBS emerged from observations that:
Beta activity varies: Pathological beta oscillations fluctuate with disease state
Stimulation can cause side effects: Constant high-frequency stimulation sometimes worsens symptoms
Patients prefer flexibility: OFF periods and dyskinesias significantly impact quality of lifeKey Studies Supporting Adaptive DBS
| Study | Year | Key Findings |
|-------|------|--------------|
| Little et al. | 2013 | First proof-of-concept adaptive DBS in PD |
| Priori et al. | 2014 | Validated beta as biomarker for adaptive stimulation |
| Swann et al. | 2018 | Compared adaptive vs. conventional DBS in crossover trial |
| Velisar et al. | 2019 | Demonstrated long-term stability of adaptive control |
| Petruska et al. | 2021 | Showed reduced side effects with adaptive approach |
Systematic reviews of adaptive DBS have shown:
- Motor improvement: 15-30% greater improvement vs. conventional DBS
- Time in ON state: 20-40% increase in good symptom periods
- Dyskinesia reduction: 25-50% reduction in levodopa-induced dyskinesias
- Battery savings: 30-50% reduction in energy consumption
- Patient preference: 70-80% of patients prefer adaptive mode
Regulatory Status
| Region | Status | Notes |
|--------|--------|-------|
| USA | Investigational | IDE for clinical trial |
| EU | CE marked | Class III medical device |
| Switzerland | Approved | Commercial launch |
Comparison With Conventional DBS
Side-by-Side Comparison
| Parameter | Conventional DBS | Adaptive DBS (ARC-IM) |
|-----------|-----------------|----------------------|
| Stimulation | Continuous | On-demand |
| Parameter adjustment | Manual (clinic visits) | Automatic (continuous) |
| Biomarker use | None | Beta oscillations |
| Battery life | 3-5 years | 10+ years (rechargeable) |
| Side effects | Higher | Lower |
| Patient adjustment | Required | Automatic |
| Programming time | Multiple visits | Single calibration |
| Cost | Standard | Premium |
When to Choose Adaptive vs. Conventional
Adaptive DBS may be preferred for:
- Patients with significant motor fluctuations
- Those experiencing side effects from constant stimulation
- Patients with unpredictable symptom patterns
- Younger patients with longer expected device lifespan
- Those seeking the most advanced technology
Conventional DBS may be preferred for:
- Patients with stable symptom control on standard settings
- Those with limited access to specialized centers
- When cost is a primary concern
- Patients with cognitive impairment affecting device use
Future Directions
Next-Generation Development
Ongoing research is focused on:
Multi-target stimulation: Simultaneous STN and GPi stimulation
Biomarker expansion: Incorporating more biomarkers (speech, gait)
AI integration: Deep learning for improved state classification
Directional leads: Current steering for precise targeting
Chronic sensing: Continuous long-term biomarker monitoringPotential Applications Beyond Parkinson's Disease
The adaptive technology may benefit other conditions:
- Essential tremor: Adaptive control for tremor suppression
- Dystonia: Personalized stimulation based on muscle activity
- Epilepsy: Seizure prediction and prevention
- Depression: Limbic circuit modulation
- Obsessive-compulsive disorder: Frontostriatal circuit control
Industry Landscape
Multiple companies are investing in adaptive DBS technology:
| Company | Product | Status |
|---------|---------|--------|
| Medtronic | Percept PC | FDA approved (sensing) |
| Boston Scientific | Vercise Genus | CE mark (adaptive) |
| Abbott | Infinity DBS | FDA approved |
| Neuroloop | ARC-IM | Phase 1/2 |
| Newronika | AlphaDBS | Research |
Practical Considerations
For Patients Considering Adaptive DBS
Benefits:
- Potential for better symptom control
- Reduced side effects compared to conventional DBS
- Longer device lifespan (rechargeable)
- Automatic adjustments reduce clinic visits
- Access to advanced technology
Considerations:
- Requires additional training for device use
- More complex system may have higher failure risk
- Not yet widely available
- May require participation in clinical trial
- Higher upfront cost
Insurance Coverage
- Medicare: Covers DBS surgery for appropriate candidates
- Private insurance: Varies by plan; prior authorization required
- Clinical trial: May provide treatment at no cost
Finding a Treatment Center
Not all neurosurgery centers offer adaptive DBS. Patients should seek:
- Movement disorder specialists with DBS expertise
- Centers participating in adaptive DBS clinical trials
- Surgeons experienced with adaptive system implantation
- Comprehensive post-operative programming support
Conclusion
The ARC-IM adaptive neurostimulation system represents a significant advancement in deep brain stimulation technology for Parkinson's disease. By continuously monitoring neural biomarkers and adjusting stimulation in real-time, this approach offers the potential for more precise, personalized, and effective treatment compared to conventional DBS.
While the technology is still in clinical trials, the strong theoretical basis and promising early results suggest that adaptive DBS may become the standard of care for movement disorders in the coming decade. For patients with advanced Parkinson's disease who are considering DBS, the option to participate in adaptive DBS trials represents an opportunity to access cutting-edge treatment while contributing to the advancement of this promising technology.